OCGN Archives - BioTuesdays

Developments

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...

October 22, 2024

Markets

Cantor starts Ocugen at OW; PT $4.50

Cantor Fitzgerald launched coverage of Ocugen (NASDAQ:OCGN) with an “overweight” rating and price target of $4.50. The stock closed at $2.17 on June 1. Ocugen is a clinical-stage biotechnology company focused on...

June 2, 2022

Markets

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

February 4, 2021

Developments

Ocugen OCU400 gets fourth FDA orphan drug designation for retinal disease

Ocugen’s (NASDAQ:OCGN) OCU400 received FDA orphan drug designation for the treatment of PDE6B gene mutation-associated retinal disease. OCU400 consists of a nuclear hormone receptor gene, NR2E3, which is delivered to...

August 10, 2020

Developments

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

June 1, 2020

Developments

Ocugen genetic modifier for retinitis pigmentosa published in Nature Gene Therapy

Peer-reviewed, Nature Gene Therapy, published Ocugen’s (NASDAQ:OCGN) preclinical data of nuclear hormone receptor gene, NR2E3, as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases...

March 3, 2020

Feature

Ocugen developing therapies for rare and underserved eye diseases

Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...

February 25, 2020

Tag - OCGN

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

Cantor starts Ocugen at OW; PT $4.50

HCW ups Ocugen to buy from neutral; PT $4.50

Ocugen OCU400 gets fourth FDA orphan drug designation for retinal disease

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen genetic modifier for retinitis pigmentosa published in Nature Gene Therapy

Ocugen developing therapies for rare and underserved eye diseases

General

More